Compare FR & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FR | PRAX |
|---|---|---|
| Founded | 1993 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 8.3B |
| IPO Year | 1996 | 2020 |
| Metric | FR | PRAX |
|---|---|---|
| Price | $58.89 | $288.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 19 |
| Target Price | $72.25 | ★ $638.68 |
| AVG Volume (30 Days) | ★ 819.0K | 357.8K |
| Earning Date | 10-14-2026 | 11-04-2026 |
| Dividend Yield | ★ 3.36% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.66 | N/A |
| Revenue | ★ $727,076,000.00 | N/A |
| Revenue This Year | $8.07 | N/A |
| Revenue Next Year | $6.68 | $39,590.54 |
| P/E Ratio | $36.55 | ★ N/A |
| Revenue Growth | ★ 8.58 | N/A |
| 52 Week Low | $50.29 | $50.31 |
| 52 Week High | $69.88 | $392.70 |
| Indicator | FR | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 27.51 | 35.63 |
| Support Level | $58.87 | $282.35 |
| Resistance Level | $60.50 | $354.17 |
| Average True Range (ATR) | 0.88 | 14.63 |
| MACD | -0.15 | -1.65 |
| Stochastic Oscillator | 3.27 | 21.96 |
First Industrial Realty Trust Inc is a real estate investment trust that owns, manages, acquires, sells, develops, and redevelops industrial real estate. Through its fully integrated operating and investing platform, the company provides facilities and customer service to multinational corporations and regional firms that are essential for their supply chains. The company serves a diverse tenant base across various sectors, including e-commerce, logistics, transportation, manufacturing, retail, consumer services, food and beverage, building materials, wholesale goods, health services, and government.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.